Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Roswell Park Researchers Evaluate Promising Drug For Intolerant Or Resistant CML
Roswell Park Cancer Institute (RPCI) scientists are investigating a promising drug for chronic myeloid leukemia (CML) patients who have become intolerant or resistant to standard therapies. Meir Wetzler, MD, Department of Medicine at Roswell Park Cancer Institute, analyzed the effectiveness of omacetaxine (OM) in an ongoing phase II clinical study and will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 - June 2, in Orlando, FL.
generic viagra online
Amgen Announces KRAS Safety Update To U.S. Prescribing Information For Vectibix(R) (Panitumumab)
Amgen Inc. (Nasdaq: AMGN) announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix((R)) (panitumumab). This decision follows the FDA"s December 2008 Oncologics Drugs Advisory Committee (ODAC) meeting where the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFr antibody was discussed.
News of the day
Why Does Eczema Often Lead To Asthma?
Many young children who get a severe skin rash develop asthma months or years later. Doctors call the progression from eczema, or atopic dermatitis, to breathing problems the atopic march. In this week"s issue of PLoS Biology, scientists at Washington University School of Medicine in St. Louis report another step taken towards understanding the process of atopic march. Their findings show that a substance that is secreted by damaged skin can circulate through the body and trigger asthmatic symptoms in laboratory mice when exposed to eczema-causing or dermatitis-causing agents, also known as allergens . The researchers suggest that early treatment of skin rash and inhibition of the trigger substance might block asthma development in young patients with eczema.
Endocrinology

Scientists Develop Mathematical Model To Predict The Immune Response To Influenza

Researchers at the University of Rochester have developed a mathematical model to predict immune responses to infection with influenza A viruses, including novel viruses such as the emergent 2009 influenza A (H1N1). This model examines the contributions of specific sets of immune cells in fighting influenza A virus. The model also helps predict when during the immune response to viral infection antiviral therapy would be most effective. The project was conducted by investigators funded through the Modeling Immunity for Biodefense program, a program established in 2005 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to improve preparedness for emerging and re-emerging pathogens. When an individual is infected by a virus, a network of immune cells becomes immediately engaged, taking up viral particles and presenting pieces of the virus - antigens - to specialized white blood cells, thereby initiating a virus-specific response. The responding cells include T cells - which either directly attack and eliminate virus-infected cells or help other immune cells fight the virus - as well as B cells, which produce antibodies that bind and neutralize the virus. The mathematical model developed by the research team generates immune response scenarios reflecting multiple variables, including the pathogenicity of the virus, numbers of responding B and T cells and function of antigen-presenting cells, in the lungs and lymph nodes. Their model suggests that prolonged viral infection limits the production of T cells and inhibits antigen presentation to immune cells. Confirming previous findings, the mathematical model predicts that antiviral therapy is most effective in reducing the spread of the virus when given within two days after infection. The research team tested the accuracy of their model in mice infected with influenza A virus. They next plan to apply the model to human populations and continue to improve the model as more data become available. In addition to the investigators in Rochester, NIAID supports three additional laboratories across the United States as part of the Modeling Immunity for Biodefense program. These scientists are conducting immune modeling research with the goal of developing models to simulate host immune responses to infections or vaccination in order to better treat and prevent diseases affecting millions of people, such as seasonal flu and tuberculosis. Article: HY Lee et al. Simulation and prediction of the adaptive immune response to influenza A virus infection. Journal of Virology. DOI: 10.1128/JVI.00098-09. Who: Timothy A. Gondrç©-Lewis, Ph.D., Program Officer, Immunoregulation Section, Basic Immunology Branch, NIAID Division of Allergy, Immunology and Transplantation. Julie Wu NIH/National Institute of Allergy and Infectious Diseases


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009